about
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsRenal cell carcinoma.Current status and perspectives of patient-derived xenograft models in cancer research.Mitochondrial Deficiencies in the Predisposition to ParagangliomaHypoxia inducible factors in hepatocellular carcinomaIntegration of hypoxic HIF-α signaling in blood cancers.Discovery of a murine model of clinical PAH: Mission impossible?Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.Renal cell carcinoma: molecular characterization and evolving treatment paradigms.The hypoxia signalling pathway in haematological malignancies.Metabolic reprogramming in clear cell renal cell carcinoma.Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.Developing Cures: Targeting Ontogenesis in Cancer.The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases.The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma.The therapeutic potential of HIF-2 antagonism in renal cell carcinoma.Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.Assembly and function of bHLH-PAS complexes.PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.SREBP-1c as a molecular bridge between lipogenesis and cell cycle progression of clear cell renal carcinoma.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Modulators of 14-3-3 Protein-Protein Interactions.Targeting HIF2 in Clear Cell Renal Cell Carcinoma.The role of hypoxia-inducible factors in carotid body (patho) physiology.Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.Regulation of immunity and inflammation by hypoxia in immunological niches.Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?Establishment of a bioluminescent Renca cell line for renal carcinoma research.Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.The HIF and other quandaries in VHL disease.
P2860
Q27727998-89DF4101-7514-4540-8E24-5A9065F2FC32Q30235364-3DE08819-DDF9-453E-9EB6-D2450804DD36Q33667686-DB2A3C4C-989D-4D1A-8815-AB54E803D851Q33844924-57BF11E4-518A-48FE-87C4-A1F34BD7A4C6Q38685135-95C034DE-687E-498E-A67E-1390371F64F4Q38769432-12650D28-58D7-4189-A955-93D2A8A97320Q39089351-1D26EA5C-E8ED-4635-9346-4A49855E74C1Q39110234-C1611FF0-90B1-4042-8520-F1509692E053Q39157961-1B7ABD49-61B5-420F-88AF-7F097333D15AQ39246376-9B698FF8-6106-4E94-ACED-FD3B1C7B3CC6Q39290307-79F8CA12-57BA-42B2-A0D7-41179669A7EAQ39340415-14AD525E-B79F-444C-8D05-B19C10EDE9A5Q39441380-4C98FC2D-D31E-42C7-9413-324D1453A387Q41112435-619863E6-94D1-4EA3-AD15-5AE9AB6955BEQ41472694-E56E3466-3C8A-448B-8DF2-104399E32811Q41559175-A0B75C7D-2C21-4126-896E-722E51732816Q41574276-FC0705CC-875D-436E-8AD4-DEC76F309EF3Q41636614-C9C4C85C-93C2-45C7-97F2-F4DBD3DE2006Q41709310-7D863FC5-467C-4572-BC74-4272D90E19A2Q42320961-B8D0C83C-7401-4FEB-A652-A0D8A76F8877Q44316914-7A18EEB3-68BA-4D1F-A0BD-EB489BB8C715Q45141795-33117447-92EF-4077-BE31-1C519F259BF3Q46485254-B70771A4-6C6F-464D-A091-74480E9D44F7Q47161583-117DDDB8-DEB9-46C8-B316-AF2591C375EAQ47252459-C3AB0401-6CEE-4D54-A0D2-CEC2F97CD7D1Q47283034-03BDBCE4-E70A-4674-8A3B-F0A2781E11AEQ47402308-20BCD759-8781-4A91-9FAC-27BD554D443AQ47600932-3A759E08-2BE5-4FE6-920D-4ECB51C291E0Q47610334-976B0F69-9145-4E69-B669-E0B99D04D20DQ47611824-8F4B7B31-82C5-4050-A130-C23A6393D1AEQ47642170-6D82D928-FFB3-4824-B74D-5A4D1C48161EQ47648812-8D881173-4774-4CFD-8AB1-44093FEB1927Q47708732-5D60BAB8-5717-493E-B81D-D7B03BF3B69DQ47711163-7CF6F892-057F-43EB-8456-35AEC2E41B42Q47893488-5A90C147-2C75-4EF3-937D-5C74ECC3DE05Q48248980-408C1D01-7D2C-44E9-80B9-F4D3BE05701DQ48725316-30CBDFD8-90C0-4FAC-966E-CFEB63EF8440Q48922902-60EC6C56-CF67-4C50-A766-0C64039B061DQ49832801-47BBC119-5B67-4CE4-BE48-25DB63585352Q50026055-5813B19A-F18D-45D1-AEB2-6B99F1DC5C12
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting renal cell carcinoma with a HIF-2 antagonist.
@en
Targeting renal cell carcinoma with a HIF-2 antagonist.
@nl
type
label
Targeting renal cell carcinoma with a HIF-2 antagonist.
@en
Targeting renal cell carcinoma with a HIF-2 antagonist.
@nl
prefLabel
Targeting renal cell carcinoma with a HIF-2 antagonist.
@en
Targeting renal cell carcinoma with a HIF-2 antagonist.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting renal cell carcinoma with a HIF-2 antagonist
@en
P2093
Alana Christie
Allison Joyce
Andrea Pavia-Jimenez
Catherine Reeves
Eboni Holloman
Eli M Wallace
Eugene Frenkel
Farrah Homayoun
Haley Hill
Heather Geiger
P2860
P2888
P304
P356
10.1038/NATURE19796
P407
P577
2016-09-05T00:00:00Z